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Summary
The malaria parasite Plasmodium falciparum invades
erythrocytes where it replicates to produce invasive
merozoites, which eventually egress to repeat the
cycle. Merozoite surface protein-1 (MSP1), a prime
malaria vaccine candidate and one of the most abun-
dant components of the merozoite surface, is impli-
cated in the ligand–receptor interactions leading to
invasion. MSP1 is extensively proteolytically modi-
ﬁed, ﬁrst just before egress and then during invasion.
These primary and secondary processing events are
mediated respectively, by two parasite subtilisin-like
proteases, PfSUB1 and PfSUB2, but the function and
biological importance of the processing is unknown.
Here, we examine the regulation and signiﬁcance of
MSP1 processing. We show that primary processing
is ordered, with the primary processing site closest to
the C-terminal end of MSP1 being cleaved last, irre-
spective of polymorphisms throughout the rest of the
molecule. Replacement of the secondary processing
site, normally refractory to PfSUB1, with a PfSUB1-
sensitive site, is deleterious to parasite growth. Our
ﬁndings show that correct spatiotemporal regulation
of MSP1 maturation is crucial for the function of the
protein and for maintenance of the parasite asexual
blood-stage life cycle.
Introduction
Clinical malaria results from replication of asexual blood-
stage forms of the malaria parasite in erythrocytes. The
parasite divides within a parasitophorous vacuole (PV),
forming a multinucleated schizont that eventually under-
goes cytokinesis to produce daughter merozoites. These
are released from the infected host cell in a process called
egress, and rapidly bind to and invade a fresh host cell.
Primary interactions between the merozoite and its target
erythrocyte involve parasite surface proteins, the most
abundant of which is a large (approximately 200 kDa)
glycosyl phosphatidylinositol (GPI)-anchored protein
called merozoite surface protein-1 (MSP1) (Holder et al.,
1992; Gilson et al., 2006). In the case of the most danger-
ous malarial species, Plasmodium falciparum, MSP1 is
expressed with two associated partner proteins called
MSP6andMSP7(Holderet al.,1985;Staffordet al.,1994;
1996; Pachebat et al., 2001; Trucco et al., 2001; Kauth
et al., 2003; 2006). All three proteins are synthesized
during development of the intracellular merozoite as pre-
cursors, which assemble into a complex (referred to as
MSP1/6/7) at the parasite plasma membrane. Just before
egress, all three proteins in the complex are proteolytically
modiﬁed by the action of a single subtilisin-like serine
protease called PfSUB1, which is released into the PV
lumen from specialized organelles called exonemes (Yeoh
et al., 2007; Koussis et al., 2009). This so-called primary
proteolytic processing of MSP1/6/7 involves cleavage of
theMSP1precursor(whichexistsintwomajorallelicforms
in P. falciparum) into four or ﬁve fragments (Holder et al.,
1985;1987;Lyonet al.,1986;1987;McBrideandHeidrich,
1987), whereas both MSP6 and MSP7 are N-terminally
truncated (Stafford et al., 1996; Pachebat et al., 2001;
2007; Trucco et al., 2001). The resulting processed prod-
ucts remain non-covalently associated on the merozoite
surface until egress and invasion of a fresh erythrocyte.
Duringinvasion,thebulkofthecomplexiscompletelyshed
from the free merozoite surface through the action of a
second, membrane-bound subtilisin-like protease called
PfSUB2, which is discharged onto the parasite surface
from a set of apically disposed parasite organelles called
micronemes (Blackman and Holder, 1992; Harris et al.,
2005). This secondary processing step takes the form of a
single cleavage on the C-terminal side of a Leu residue
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NISQ(Blackmanet al.,1990).Thissequenceiscompletely
refractory to cleavage by PfSUB1 (Koussis et al., 2009),
and we have previously hypothesized that this may be an
important factor in the spatiotemporal regulation of the two
processing steps; primary processing of the MSP1/6/7
complex is initiated by release of PfSUB1 from exonemes
into the PV lumen just before egress, but secondary pro-
cessing cannot be mediated by PfSUB1 so can only occur
upon subsequent release of PfSUB2 from micronemes
following egress. MSP1 has been extensively studied due
to its potential as a vaccine candidate, as antibodies
against it can prevent invasion in vitro and protect against
blood-stage challenge in vivo [see Holder (2009) and
Vekemans and Ballou (2008) for recent reviews].Addition-
ally, there is accumulating evidence that MSP1 has a
crucialroleinmediatingadhesiveinteractionsbetweenthe
invading merozoite and host erythrocyte (Su et al., 1993;
Goel et al., 2003; Li et al., 2004; Boyle et al., 2010). In
support of this, gene knockout studies have shown that
MSP1 (O’Donnell et al., 2000; Drew et al., 2004; Combe
et al., 2009), but not MSP7 (Tewari et al., 2005; Kadekop-
pala et al., 2008) or MSP6 (E. Knuepfer and A. Holder,
pers. comm.), is indispensable in the asexual life cycle of
the parasite.All Plasmodium species possess orthologues
of MSP1, and the protein is subjected to a similar two-step
proteolytic processing in all those species where the phe-
nomenon has been examined (O’Dea et al., 1995; Black-
man et al., 1996; Wiser et al., 1997; Jennings et al., 1998).
Small molecules or antibodies that inhibit PfSUB1 activity
or interfere with PfSUB2-mediated shedding of the MSP1/
6/7 complex can prevent invasion (Blackman et al., 1994;
Fleck et al., 2003; Koussis et al., 2009), leading to sugges-
tions that proteolytic maturation of MSP1 is essential for
invasion. However, both PfSUB1 and PfSUB2 have sub-
strates other than MSP1 (Howell et al., 2003; Yeoh et al.,
2007; Koussis et al., 2009), so the speciﬁc importance of
MSP1 maturation and the biological signiﬁcance of its
spatiotemporal regulation is unknown.
Here, we have used a mutagenesis-based approach
to address this question. We ﬁrst show that maturation
of P. falciparum MSP1 by PfSUB1 is an ordered
process, in which the primary processing site closest to
its C-terminal end (the 38/42 site) is cleaved last, irre-
spective of polymorphisms throughout the rest of the
molecule. Second, we demonstrate that perturbation of
the processing order by replacing the secondary pro-
cessing site in MSP1 with a PfSUB1-sensitive sequence
that is cleaved more efficiently than the 38/42 site,
cannot be tolerated by the parasite. Our results provide
the ﬁrst genetic evidence that correct regulation of
MSP1 processing is critical for the function of the
protein, and for maintenance of the erythrocytic life cycle
of the malaria parasite.
Results
Most primary processing sites in MSP1 are dimorphic
Like many blood-stage malarial surface proteins, P. falci-
parum MSP1 is highly polymorphic. Extensive early work
showed that the protein can be divided into 17 regions or
blocks of variable, less variable (semi-conserved) and
conserved (non-polymorphic) sequence (Tanabe et al.,
1987). Polymorphism in the variable regions results from
limited recombination between genes encoding two major
dimorphic forms of MSP1, typiﬁed by those expressed by
the 3D7 and Wellcome P. falciparum isolates (Tanabe
et al., 1987; 2007; Miller et al., 1993). A third relatively
uncommon MSP1 form, initially identiﬁed in the RO-33
parasite isolate, entirely lacks block 2 (which is composed
of variable Ser–Xaa–Xaa tripeptide repeats) but is other-
wise similar to the 3D7 type (Certa et al., 1987; Peterson
et al., 1988; Tanabe et al., 2007). Previous work by
us (Blackman et al., 1991; Cooper and Bujard, 1992;
Stafford et al., 1994; Koussis et al., 2009) and others
(Heidrichet al.,1989)haspreciselymappedalltheprimary
processing sites in both the 3D7 and Wellcome types of
MSP1. To examine the degree of amino acid conservation
around these positions, sequences ﬂanking the cleavage
sites in all available full and partial P. falciparum MSP1
sequences deposited in PlasmoDB (http://plasmodb.org/
plasmo/) and GenBank (http://www.ncbi.nlm.nih.gov/)
were examined by multiple alignment. Sequences from a
total of 35 complete (29 3D7-type and six Wellcome-type)
and 130 partial MSP1 sequences were incorporated into
the analysis. This allowed us to make two main observa-
tions regarding the sites. First, although all the cleavage
sites (aside from the 3D7 type-speciﬁc 83int cleavage) are
positionally conserved within the MSP1 sequences, all lie
within semi-conserved or variable regions of the protein.
However, within each form of MSP1, the alignments reveal
no microheterogeneity in the residues closely ﬂanking the
cleavage sites, aside from the presence in just two depos-
ited sequences of a Thr-to-Ala substitution at the P4′
position of the 83/30 cleavage site in the 3D7 form (Fig. 1).
Our second observation was that of all the primary pro-
cessing sites, only the 38/42 site (i.e. that closest to the
C-terminus of MSP1) shows any signiﬁcant identity
between the dimorphic MSP1 forms. At this site, all four
non-prime side amino acid residues (positions P4–P1 in
Schechter and Berger nomenclature: Schechter and
Berger, 1967) that are usually important for substrate
recognition by subtilisin-like proteases (Siezen and Leu-
nissen, 1997), plus the P5, P6 and P1′ residues, are
identical between the MSP1 forms.
Earlier work on PfSUB1 substrate speciﬁcity deﬁned a
consensus PfSUB1 recognition motif of Ile/Leu/Val/Thr/
Phe–Xaa–Gly/Ala–Paa(not Leu)↓Xaa (where Xaa is any
amino acid residue and Paa tends to be a polar residue),
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more of the proximal ﬁve positions on the prime side of the
scissile bond (Koussis et al., 2009). Beyond this, the
requirements for optimal substrate cleavage by PfSUB1
are unknown.All the P. falciparum MSP1 primary process-
ing sites ﬁt this consensus, but as different amino acid
target sequences are usually recognized with different
affinities by proteases, our observations led us to formu-
late two hypotheses: ﬁrst, that the different cleavage sites
within MSP1 are likely to be cleaved by PfSUB1 at differ-
ent relative rates; and second, that the 38/42 site may be
of special signiﬁcance in the processing pathway. Our
next experiments focused on testing these predictions.
Primary processing of MSP1 is ordered
To examine the relative rates of cleavage at the various
MSP1 primary processing sites we exploited a modiﬁca-
tion of a previously used assay (Koussis et al., 2009) in
which protease inhibitor-treated, permeabilized schizonts
containing predominantly unprocessed MSP1 precursor
are exposed in vitro to exogenously added recombinant
PfSUB1 (rPfSUB1). This assay is designed to mimic
authentic primary processing, using the native, GPI-
anchored, parasite-derived MSP1 as a substrate. To
follow the course of processing over time, digests were
sampled at intervals following addition of rPfSUB1 and
examined by Western blot using monoclonal antibodies
(mAb) or polyclonal antibodies speciﬁc for epitopes within
both the MSP183 and MSP142 processing products.
Figure 2 shows the results of a typical processing
assay using schizonts expressing the 3D7-type MSP1.
Processing was observed to proceed to the ﬁnal
products through two transient high molecular weight
intermediates, one of which (approximately 120 kDa)
was recognized by mAb 89.1 but not mAb X509
(Fig. 2A left-hand side), and the other of which (approxi-
mately 90 kDa) was recognized by mAb X509 but not
mAb 89.1 (Fig. 2A right-hand side). These observations
can only be accommodated by a model in which cleav-
age occurs ﬁrst at the central 30/38 site (Fig. 2B). Sub-
sequent to this, the MSP183 product, followed by its
N-terminally truncated form (both detected by mAb
89.1), appeared rapidly compared with the relatively
slow rate of appearance of the ﬁnal MSP142 product
detected by mAb X509. This led us to conclude that
cleavage at the 38/42 site is slow relative to cleavage at
all the other sites.
To independently test this interpretation, we next exam-
ined processing by rPfSUB1 of a full-length recombinant
form of 3D7 MSP1 (Supporting information Fig. S1). Once
again, probing the blots with mAb 89.1 or mAb X509
showed that processing progressed through two different-
sized high molecular weight intermediates, each of which
was recognized by only one of the two mAbs, indicating
that the ﬁrst cleavage occurs at the central 30/38 site.
Cleavage then occurred at the 83/30 site, followed by
cleavage at the 83int site. However, once again conver-
sion of the mAb 89.1-reactive intermediate to smaller
fragments was rapid compared with breakdown of the
Fig. 1. Most primary processing site sequences diverge between the two MSP1 allelic types.
Primary proteolytic processing of MSP1 by PfSUB1 results in the production of the MSP183, MSP130, MSP138 and MSP142 fragments (top
centre). The amino acid sequences within which cleavage occurs are shown for the two major dimorphic forms of MSP1, typiﬁed by those of
the 3D7 and Wellcome isolates (centre). Also shown is an additional cleavage site (called 83int, indicated by dotted lines) that occurs only in
the 3D7-type MSP1. The only detected microheterogeneity in the cleavage sites is a Thr-to-Ala substitution in the P4′ position of the 3D7-type
83/30 cleavage site. The positions of the primary cleavage sites relative to the distribution of conserved (open), variable (black) and
semi-conserved (grey) blocks within MSP1, numbered 1–17 according to Tanabe et al. (1987) are shown (bottom). The sequence at which
PfSUB2-mediated secondary processing occurs is also shown (top right). Note that PfSUB1 cannot cleave C-terminal to a Leu residue, and
the secondary processing site is completely refractory to PfSUB1 (Withers-Martinez et al., 2002; Yeoh et al., 2007; Koussis et al., 2009).
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38/42 site is processed last.
To explore whether the above-described processing
pattern holds for the other major dimorphic form of MSP1,
we returned to the cell-based processing assay, this time
using permeabilized schizonts from a parasite clone (T9/
94) expressing the Wellcome-type MSP1. In this case
formation of MSP183 did not proceed through an interme-
diate detectable with mAb 89.1 (Fig. 3A), suggesting
rapid, preferred cleavage at the 83/30 site. In contrast, the
antibodies reactive with the C-terminal MSP142 fragment
detected two transient intermediates much larger than the
ﬁnal MSP142 product, suggesting that cleavage at both the
83/30 and 30/38 sites took place more rapidly than cleav-
age at the 38/42 position (Fig. 3B). Collectively, our
results suggest that for both major forms of MSP1,
primary processing by PfSUB1 is an ordered event. This
order appears different between the MSP1 types, but in
both cases cleavage at the 38/42 site occurs last.
Peptides based on the 38/42 MSP1 processing site are
poor PfSUB1 substrates relative to peptides based on
the other primary processing sites
Previous work has shown that short synthetic peptides
based on known PfSUB1 cleavage sites – including the P.
falciparum MSP1 primary processing sites – can act as
substrates for the protease and are correctly cleaved by
rPfSUB1 (Yeoh et al., 2007; Koussis et al., 2009). To
investigate whether the ordered primary processing of
MSP1 by PfSUB1 was a result of the differences in
primary amino acid sequence at the various sites, pep-
tides based on the three positionally conserved process-
ing sites (the 83/30, 30/38 and 38/42 sites) were
compared for their susceptibility to cleavage by PfSUB1.
To do this, pairs of N-acetylated decapeptides corre-
sponding to sequences encompassing the sites were
mixed at equimolar ratios, then initial rates of cleavage by
rPfSUB1 established by analytical reversed-phase high-
performance liquid chromatography (RP-HPLC). Under
such conditions, because the peptides effectively act as
competing substrates, their relative initial rates of hydroly-
sis are a function of the ability of PfSUB1 to discriminate
between them, and so are directly proportional to their
relative kcat/Km values, irrespective of their actual concen-
tration (Cornish-Bowden, 2004). This analysis allowed us
to estimate relative initial cleavage rates between peptide
pairs, and to conﬁdently rank most of the peptides in order
of their susceptibility to cleavage. For the three Wellcome
MSP1-derived peptides (Fig. 4A–C), the rank order was
30/38 > 83/30 > 38/42 in order of best to worst substrate,
with the 30/38 peptide being initially cleaved approxi-
Fig. 2. PfSUB1-mediated proteolytic
processing of the 3D7 MSP1 is ordered.
A. Typical time-course of digestion of native
3D7 P. falciparum-derived MSP1.
Saponin-permeabilized 3D7 schizonts were
incubated at 37°C in the presence of
rPfSUB1. Samples taken at intervals were
analysed by Western blot, probing with either
the MSP183-speciﬁc mAb 89.1 (left-hand side),
or the MSP142-speciﬁc monoclonal antibody
X509 (right-hand side). For both blots the
MSP1 precursor is indicated with a black
arrow, processing intermediates are marked
with an open arrow, or closed round or
square-head lollipop, while terminal
processing products are marked with an open
round or square-head lollipop. No processing
was observed in the absence of added
rPfSUB1 (not shown).
B. Schematic of the order of 3D7-type MSP1
primary processing, determined from the
digestion assay shown in (A). Individual
processed species are marked with arrow or
lollipop symbols to aid comparison with the
corresponding bands on the blots.
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the 83/30 cleaved ﬁvefold more rapidly than the 38/42
peptide. This order is different to that observed when
using the intact protein as substrate, but in both cases the
38/42 site appeared to be the least preferred. In the case
of the 3D7 MSP1-derived peptides, the peptide based on
the 83/30 site behaved aberrantly under the RP-HPLC
conditions used, eluting as a very broad peak, and so was
excluded from the comparison. However, a comparison of
the 3D7-type 30/38 and 38/42 peptides (Fig. 4D) showed
again that the 30/38 peptide was cleaved much faster
(initial rate 17-fold faster) than the 38/42 peptide. These
results show that peptides based on the 38/42 sites of
both the Wellcome and 3D7 MSP1 are very poor sub-
strates compared with all other peptides tested. This is
consistent with our analysis of cleavage of intact MSP1,
and suggests that the reason why cleavage at the 38/42
sites occurs more slowly than cleavage at the other
primary processing sites is at least in part due to the
less-preferred nature of the primary sequence at those
sites.
Substitution of the MSP1 secondary processing site with
a PfSUB1-sensitive site alters the pattern of primary
processing and cannot be tolerated by the parasite
Following primary processing by PfSUB1 and merozoite
egress, the entire MSP1/6/7 complex is shed from the free
merozoite surface by a single further cleavage at a
QG/DML↓NISQ motif, mediated by PfSUB2 (Fig. 1). This
secondary processing site is completely refractory to
PfSUB1 (Koussis et al., 2009). To assess the biological
importance of MSP1 processing, we next investigated the
effect on parasite viability of selectively perturbing the
processing. To do this, we decided to examine whether
the secondary processing site could be modiﬁed to render
it cleavable by PfSUB1, anticipating that this might result
in cleavage at the secondary processing occurring pre-
maturely, concomitant with primary processing. As the
time-scale between discharge of PfSUB1 into the PV and
eventual schizont rupture may be very short (minutes or
even seconds), we considered it important that – to guar-
antee cleavage at the modiﬁed site – we inserted a site
that was more efficiently cleaved than the least-preferred
primary processing site, the 38/42 site. Based on the
PfSUB1 consensus recognition motif, described above,
we designed an ‘artiﬁcial’ sequence, FISGQ↓SETDH (the
arrow indicates the predicted scissile bond), which we
predicted would be efficiently cleaved by PfSUB1. To
conﬁrm this, we ﬁrst tested the synthetic decapeptide
Ac-FISGQSETDH for sensitivity to cleavage in vitro by
rPfSUB1. As shown in Fig. S2, this peptide was indeed
cleaved at the predicted Gln–Ser bond, with substantially
faster kinetics (approximately 4.5-fold faster) than both
the 3D7 and Wellcome-type 38/42 peptides. To test the
amino acid sequence for susceptibility to PfSUB1 in the
context of an intact protein, we then introduced the same
sequence into a recombinant form of the C-terminal ‘half’
Fig. 3. PfSUB1-mediated proteolytic
processing of the Wellcome-type MSP1 is
ordered.
A. Typical time-course of digestion of native
T9/94 P. falciparum-derived MSP1.
Saponin-permeabilized T9/94 schizonts were
incubated at 37°C in the presence of
rPfSUB1. Samples taken at intervals were
analysed by Western blot, probing with either
the MSP183-speciﬁc mAb 89.1 (left-hand side),
or a MSP142-speciﬁc polyclonal antibody
(right-hand side). For both blots the MSP1
precursor is indicated with a black arrow,
processing intermediates are marked with an
open arrow, or closed square-head lollipop,
while terminal processing products are
marked with an open round or square-head
lollipop. No processing was observed in the
absence of added rPfSUB1 (not shown).
B. Schematic of the order of Wellcome-type
MSP1 primary processing, determined from
the digestion assay shown in A. Individual
processed species are marked with arrow or
lollipop symbols to aid comparison with the
corresponding bands on the blots.
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directed mutagenesis to replace residues ﬂanking the
secondary processing site. As shown in Fig. 5, incubation
of this modiﬁed recombinant protein with rPfSUB1
resulted in an additional speciﬁc processing step, consis-
tent with cleavage at the modiﬁed site and resulting in the
formation of a 33 kDa processing product analogous to
that produced upon PfSUB2-mediated secondary pro-
cessing of the authentic parasite MSP1 (Blackman and
Holder, 1992). Conversion to the 33 kDa product took
place with production of an intermediate species likely
resulting from cleavage at the introduced site before
cleavage at the 38/42 site (Fig. 5A and C). These results
provided convincing evidence to suggest that, when intro-
duced into MSP1, the artiﬁcial sequence could be recog-
nized and cleaved by PfSUB1 in a similar manner to an
authentic PfSUB1 cleavage site. Importantly, the indica-
tions that it was a better substrate than the 38/42
sequence encouraged us in our prediction that it would be
efficiently cleaved by PfSUB1 when incorporated into the
authentic, parasite-surface MSP1.
In light of the above ﬁndings, we set about investigating
the consequences of similarly modifying the msp1 gene in
the 3D7 P. falciparum clone, using targeted homologous
recombination. For this we exploited a previously used
strategy (Yeoh et al., 2007) in which we introduced into
the parasite circular DNA constructs containing targeting
sequence corresponding to internal msp1 sequence,
fused in frame to a short stretch of synthetic ‘recodonized’
sequence encoding the C-terminal domain of MSP1
(Figs 6 and S3). The synthetic sequence shares low iden-
tity at the nucleotide level with the authentic msp1 gene,
Fig. 4. Synthetic peptides based on the 38/42 processing sites in the 3D7 and Wellcome-type MSP1 are poor substrates for PfSUB1.
RP-HPLC chromatograms showing partial digestion by rPfSUB1 of N-acetylated decapeptides based on the primary processing sites in the
Wellcome-type (A–C) and 3D7-type (D) MSP1. The top chromatogram in each panel shows the elution proﬁle of an equimolar mix of the
undigested peptides, while the lower chromatogram shows the RP-HPLC elution proﬁle after partial digestion with rPfSUB1. Identities of major
peaks as determined by electrospray mass spectrometry (data not shown but see Koussis et al., 2009), are indicated. As described previously
(Yeoh et al., 2007; Koussis et al., 2009), highly polar cleavage products were usually not retained by the RP-HPLC column but eluted in the
column ﬂow-through. Note that for determination of relative initial rates of cleavage, cleavage rates were compared when the faster-cleaved
peptide of each pair was digested by  10%, as described in Experimental procedures. For clarity, digestion was allowed to proceed much
more than 10% in most of the proﬁles shown in this ﬁgure.
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stream of the junction between the authentic and syn-
thetic sequence. Two integration constructs were used,
one of which (pMSP1chimWT) was designed to leave the
amino acid sequence at the secondary processing
site unaltered following integration, while the other
(pMSP1chimSUB2to1) was designed to replace the
secondary processing site with the FISGQ↓SETDH
sequence shown above to be efficiently targeted by
PfSUB1. The DNA constructs were otherwise identical. In
addition, the constructs were designed to produce upon
integration a chimeric gene in which the 3′ region (the
synthetic sequence) encoded a Wellcome-type MSP1
C-terminal domain. This differs from the 3D7 sequence at
just 5-amino-acid residues. Importantly, it can be distin-
guished from the 3D7-type domain by its reactivity with
mAb 111.4, the epitope of which is not present in the 3D7
MSP1 as it requires the presence of a Gln residue at a
dimorphic position 14 residues downstream of the sec-
ondary processing site (Fig. S3) (Chappel and Holder,
1993; Tolle et al., 1995); the 3D7 sequence has a Glu
residue at that position. Thus, correct integration of either
construct was expected to effectively epitope-tag the
resulting MSP1 chimeric gene product, enabling conﬁr-
mation of the desired homologous recombination event at
the protein level.
The pMSP1chimWT and pMSP1chimSUB2to1 con-
structs were separately transfected in triplicate into 3D7
parasites and the cultures drug cycled to select for inte-
gration events. After four cycles of drug treatment, poly-
merase chain reaction (PCR) analysis indicated the
presence of homologous recombination events in all
three parasite lines transfected with pMSP1chimWT
(Fig. 7A). In contrast, a weak PCR-positive result was
obtained with only one of the lines transfected with
pMSP1chimSUB2to1, and then only after seven drug
cycles over an extended period of 8 months (Fig. 7A),
suggesting that integration of that construct into the
Fig. 5. Substitution of the MSP1 secondary processing site with a PfSUB1-sensitive sequence.
A. Western blot time-course analysis of rPfSUB1-mediated processing of rMSP138/42 either in wild-type form (WT) or after modiﬁcation of the
secondary processing site by site-directed mutagenesis to convert it to a predicted PfSUB1-sensitive site (SUB2to1). The WT rMSP138/42
(80 kDa, arrowed) is converted to a stable 42 kDa terminal species (open round-head lollipop) equivalent to MSP142. The SUB2to1 mutant
(arrowed) is similarly converted to the normal MSP142 species (open round-head lollipop), but also undergoes an additional processing step
that converts it via an approximate 70 kDa intermediate (closed square-head lollipop) to a stable 33 kDa form (open square-head lollipop). The
2 h tracks show the results of incubation for 2 h in the absence of added rPfSUB1. The bands marked with a star are likely truncated forms of
rMSP138/42 derived from breakdown of the recombinant protein during its puriﬁcation and refolding.
B and C. Schematic depiction of processing patterns for the WT (B) and SUB2to1 mutant rMSP138/42 protein (C). The relative position of the
secondary processing site, the sequence modiﬁcations made and the region of the protein recognized by the rabbit anti-MSP142 antibodies
used to probe the blots, are indicated. Individual processed species are marked with arrow or lollipop symbols to aid comparison with the
corresponding bands on the blots.
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four integration-speciﬁc PCR products conﬁrmed that
homologous recombination had occurred, with cross-
over taking place upstream of the synthetic recodonized
Wellcome sequence, and that for the line transfected
with pMSP1chimSUB2to1, the SUB2to1 mutation had
been incorporated into the 3D7 msp1 locus as expected
(data not shown). To conﬁrm expression of the expected
chimeric MSP1 gene product in the transgenic lines, all
four lines were analysed by immunoﬂuorescence assay
(IFA) using both mAb X509 (which recognizes a 3D7-
speciﬁc epitope within the N-terminal region of MSP142),
and the Wellcome type-speciﬁc mAb 111.4. As expected,
a signiﬁcant proportion (approximately 95%) of schizonts
in the lines transfected with pMSP1chimWT showed
reactivity with both mAbs (Fig. 7B), conﬁrming that they
expressed a chimeric MSP1 distinct from the parental
3D7 MSP1. In contrast, only approximately 0.2% of sch-
izonts in the line transfected with pMSP1chimSUB2to1
showed reactivity with both antibodies. The pattern of
reactivity was identical to that in the pMSP1chimWT line,
indicating correct expression and subcellular localization
of the chimeric mutant MSP1. However, the low propor-
tion of parasites expressing the mutant protein could not
be increased by further drug cycling, and in fact these
presumed transgenic parasites could only be maintained
in the population by continued drug cycling.
One of the pMSP1chimWT-transfected parasite lines (at
drug cycle 2) and the PCR-positive pMSP1chimSUB2to1-
transfected line (at drug cycle 8) were cloned by limiting
dilution,andindividualcloneswereagainexaminedbyIFA.
No mAb 111.4-positive clones were obtained from the
pMSP1chimSUB2to1-transfected line, despite extensive
drug cycling and four independent cloning attempts. In
contrast, mAb 111.4-positive clones were easily obtained
from the pMSP1chimWT-transfected parasite line. Two of
these, clones 3D7W-E6 and 3D7W-G3, were selected and
examined further by PCR (not shown) and Southern blot.
Fig. 6. Strategy for modiﬁcation of the MSP1 secondary processing site in P. falciparum by single cross-over homologous recombination.
A. Integration construct (pMSP1chimWT or pMSP1chimSUB2to1) used for targeted homologous recombination. The plasmid contains 1036 bp
of targeting sequence (dark grey) derived from the 3D7 msp1 gene, fused in frame to synthetic recodonized sequence (sMSP1-19+) encoding
the C-terminal 119 residues of the Wellcome-type MSP1, including its GPI anchor sequence. The position of the PfSUB2 cleavage (the
secondary processing site) is arrowed. In pMSP1chimSUB2to1 this site is modiﬁed to encode a PfSUB1-sensitive sequence, but otherwise the
two constructs are identical. Because the recodonized sequence shares low identity with the authentic msp1 sequence, cross-over (dotted
lines) is expected to occur only within the targeting sequence. Pbdt 3′ untranslated region (UTR), UTR of the Plasmodium berghei
dihydrofolate reductase gene to ensure correct transcription termination and polyadenylation of the modiﬁed gene. hdhfr-ts, human
dihydrofolate reductase–thymidylate synthase cassette, providing resistance to the antifolate drug WR99210.
B. The 3D7 P. falciparum genomic msp1 locus.
C. Expected result of integration, which displaces the 3′ end of the msp1 gene downstream, and replaces it with a chimera of the native
sequence and the recodonized Wellcome-type sequence. As the integration plasmid contains only a partial msp1 open reading frame, not
preceded by a promoter, the only copy to be transcribed is the modiﬁed chimeric msp1 gene directly downstream of the endogenous
promoter. The positions of epitopes recognized by mAbs X509 and 111.4 are indicated. Restriction sites used for Southern blot analysis (see
Fig. 8), the predicted sizes of restriction products, and the position of hybridization of the probe used for Southern analysis are shown.
194 M. A. Child, C. Epp, H. Bujard and M. J. Blackman 
© 2010 Blackwell Publishing Ltd, Molecular Microbiology, 78, 187–202This conﬁrmed the expected genomic rearrangements at
the msp1 locus (Fig. 8B). In further support of this, the
MSP1 protein expressed by the two clones was reactive in
Western blots with both the 3D7-speciﬁc mAb X509 and
the Wellcome-speciﬁc mAb 111.4, conﬁrming its chimeric
nature (Fig. 8C). The clones were maintained routinely
under drug pressure (2.5 nM WR9921) to select against
any possibility of reversion to wild type by resolution of the
single cross-over event used to produce them. However,
the clones remained reactive with mAb 111.4 even after
Fig. 7. Production of transgenic P. falciparum lines expressing chimeric MSP1.
A. PCR analysis to detect correct genomic integration of the homologous recombination constructs pMSP1chimWT and pMSP1chimSUB2to1.
As controls, template DNA was prepared from the parental 3D7 clone, or input pMSP1chimWT plasmid DNA only (P). For test samples,
genomic DNA was prepared after four rounds of drug cycling from three lines transfected with pMSP1chimWT (a–c), or three lines transfected
with pMSP1chimSUB2to1 (d–f), or from one of the pMSP1chimSUB2to1-transfected line following seven drug cycles (d*). Oligonucleotide
primers used in the PCR were designed to hybridize upstream of the region used as the targeting sequence in the 3D7 MSP1 locus, as well
as to an allele-speciﬁc portion of the recodonized Wellcome sMSP1-19+ sequence in the transfection constructs (see Fig. 6C). A PCR product
of approximately 1.2 kb can therefore only be produced if the predicted integration event has taken place. The integration-speciﬁc PCR
product was detected for all three pMSP1chimWT-transfected lines but not for the pMSP1chimSUB2to1-transfected lines, except for one line
examined after seven drug cycles (d*) (arrowed).
B. IFA examination of the uncloned transgenic lines conﬁrms expression of chimeric forms of MSP1. Samples of the
pMSP1chimWT-transfected line (line a, drug cycle 4) and the pMSP1chimSUB2to1-transfected line (line d*, drug cycle 8) were double-probed
with the 3D7 MSP1-speciﬁc mAb X509 and the Wellcome MSP1-speciﬁc mAb 111.4. Whereas the parental 3D7 and T9/94 parasite lines
showed reactivity only with one or other type-speciﬁc mAb as expected, both transgenic populations contained parasites reactive with both
mAbs, indicating expression of the predicted chimeric MSP1. The proportion of schizonts in the transgenic lines reactive with both antibodies
was approximately 95% for the pMSP1chimWT-transfected line, and approximately 0.2% for the pMSP1chimSUB2to1-transfected line. Nuclei
were counterstained with DAPI. Scale bar, 5 mm.
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absence of drug (not shown). To assess the impact of the
MSP1 modiﬁcation on parasite ﬁtness, the transgenic
clones were compared with the parental 3D7 clone in
growth rate assays. No differences in growth rates were
detected(Fig. 8D),showingthatexpressionofthechimeric
MSP1 containing an authentic PfSUB2 cleavage site has
no discernible effect on parasite viability. Collectively, the
ease with which these transgenic parasites were estab-
lished, compared with our inability to isolate similar trans-
genic parasites in which the secondary processing site in
MSP1 was replaced with a PfSUB1-sensitive site strongly
suggests that interfering with the regulation of MSP1 pro-
cessing has a substantial deleterious impact on parasite
viability.
Discussion
MSP1 has attracted widespread interest in the malaria
research ﬁeld over the last three decades. A steady accu-
mulation of evidence that the protein plays a key role in
erythrocyte invasion by the malaria merozoite, bolstered
by extensive data supporting its potential as a candidate
vaccine antigen, have prompted efforts to understand the
function of MSP1. The fact that MSP1 is dramatically
proteolytically modiﬁed at or around the point of invasion
Fig. 8. Transgenic P. falciparum clones
stably expressing a chimeric MSP1 with an
unmodiﬁed secondary processing site are
phenotypically normal.
A. IFA examination of transgenic clones
3D7W-E6 and 3D7W-G3 shows reactivity with
the Wellcome-speciﬁc mAb 111.4, conﬁrming
stable expression of a chimeric form of MSP1.
Nuclei were counterstained with DAPI. Scale
bar, 5 mm.
B. Southern blot analysis. Genomic DNA from
parental wild-type 3D7 parasites, and clones
3D7W-E6 and 3D7W-G3, was digested with
ClaI and EcoNI and analysed by Southern
blot using a 480 bp PCR product ampliﬁed
from the 3′ region of the 3D7 msp1 gene (see
Fig. 6). The endogenous locus band is visible
at 8.6 kb in the parental 3D7 digest, whereas
its replacement with a 6.2 kb signal in the
clone DNA digests is consistent with
modiﬁcation of the msp1 locus as predicted
(see Fig. 6).
C. Western blot conﬁrms expression of
chimeric MSP1 in the transgenic clones.
Schizont extracts from clones 3D7W-E6 and
3D7W-G3, as well as from parental 3D7 and
T9/94 (Wellcome-type) parasites, were
fractionated on 10% SDS-PAGE gels and
probed with either mAb 111.4 or mAb X509.
In contrast to the parental extracts, the
full-length MSP1 and MSP142 species from
the transgenic clones were recognized by
both mAbs. Note that mAb 111.4 recognizes a
reduction-sensitive epitope, so the left-hand
blot was from a gel run under non-reducing
conditions, whereas the right-hand blot was
from a gel run under reducing conditions.
D. Growth assay comparing in vitro replication
rates of parental 3D7 and transgenic clones
3D7W-E6 and 3D7W-G3. All three clones
were co-synchronized to a 2 h window
following 8 days (four intraerythrocytic cycles)
of culture in the absence of drug pressure).
Initial parasitaemias, measured by FACS,
were adjusted to 0.5%, then subsequently
assessed at 48 h intervals and cultures
diluted as described in Experimental
procedures. Individual points represent mean
values from triplicate samples for all three
lines and error bars represent the standard
deviations of these values. There was no
signiﬁcant difference in growth rates of the
clones.
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exploited knowledge of the substrate speciﬁcity of the
proteases involved, PfSUB1 and PfSUB2, to obtain the
ﬁrst genetic evidence that proteolytic maturation of MSP1
is critical for parasite viability, and therefore – by implica-
tion – for the function of MSP1.
Ordered proteolytic processing is a feature of several
systems in which limited proteolysis induces structural
changes in proteins required for their functional
maturation. Particularly well-studied examples of this
include the protease-mediated structural reorganization of
viral capsid proteins necessary for their conversion into
mature, infectious forms [for reviews see Steven et al.
(2005); Byrd and Hruby (2006); Ganser-Pornillos et al.
(2008)]. In the case of retroviral Gag polyprotein, which is
cleaved at several positions by the same virally encoded
aspartic protease, mutations that prevent cleavage at
certain sites, or that induce imprecise cleavage, or that
alter the order of cleavage, all severely ablate viral infec-
tivity (e.g. Craven et al., 1993; Pettit et al., 1994). These
and other similar observations have led to suggestions
that ordered cleavage has an important role in assuring
the irreversibility of the induced conformational shifts that
lead to the formation of the mature virus particle. Our
examination of rPfSUB1-mediated cleavage of both
parasite-derived and recombinant MSP1 indicated a hier-
archy of cleavage rates at the different primary processing
sites which – though slightly different between the two
major MSP1 types – in both cases indicated that cleavage
at the 38/42 site occurred last. Simplistically, ordered
cleavage at multiple sites by a single protease may be
predicted to be determined by either the primary amino
acid sequence at the processing sites or the accessibility
of the various sites to the protease. Should cleavage
induce conformational changes in a protein, the latter
element might alter during the course of processing, and
therefore cleavage at particular sites may depend on prior
processing at other sites. Our further examination of
MSP1 primary processing using peptides based on the
different sites was therefore important in that it suggested
that the order may at least in part be explained by the
primary amino acid sequence at the different sites;
steady-state cleavage rates of peptides based on the
38/42 sites were in all cases slower than that of the other
peptides tested. The correlation between the protein and
peptide data was not perfect, however; the observation
that processing of the 83/30 site in the Wellcome-type
MSP1 takes place before cleavage at the central 30/38
site was not consistent with the corresponding peptide
results, where the 30/38 peptide was clearly cleaved more
rapidly than the 83/30 peptide. We did not examine this
issue further here, but it does suggest that factors other
than primary sequence may be important in determining
the order of cleavage. Whatever the case, by analogy with
the examples referred to above, our ﬁnding that pro-
teolytic processing of MSP1 by PfSUB1 is ordered is
consistent with the proteolysis having a functional role. It
may be important for the 38/42 site to be processed last,
and the limited sequence divergence between the two
major MSP1 forms at this site may indicate selective pres-
sure to maintain this property. It is worth noting that cleav-
age by PfSUB1 of SERA5, a PV-resident putative papain-
like protease, also occurs in a stepwise manner, with
cleavage at a position referred to as site 1 preceding
cleavage at a second sequence referred to as site 2 (Li
et al., 2002; Yeoh et al., 2007). Peptides based on site 1
are much better substrates that those based on site 2
(Yeoh et al., 2007), again consistent with the notion that
the rate of cleavage by PfSUB1 is largely dependent on
the primary sequence ﬂanking the sites.
To evaluate the biological importance of the two stages
of MSP1 processing, we next explored the effects of
exchanging the secondary processing site, normally
refractory to PfSUB1, with a sequence that is sensitive to
that protease. We predicted this to have either or both of
two possible consequences: it could result in premature
‘secondary processing’ as a result of cleavage by PfSUB1
at the modiﬁed site while the merozoite was still intracel-
lular; and/or it could impact on PfSUB2 recognition of the
site, inhibiting or otherwise modifying shedding of MSP1
following egress. We were unable to directly assess the
likelihood of the second possibility, as we do not have
access to recombinant PfSUB2. However, the apparent
sequence-independent nature of PfSUB2 cleavage
(Howell et al., 2003; Harris et al., 2005) leads us to favour
the ﬁrst possibility. In support of that we found that the
peptide Ac-FISGQSETDH was a better substrate for
PfSUB1 than either of the peptides based on the 38/42
sites, and that introduction of the FISGQSETDH
sequence into a recombinant protein corresponding to the
C-terminal ‘half’ of MSP1 rendered the protein susceptible
to an additional cleavage on exposure to rPfSUB1 in vitro,
with a pattern consistent with efficient cleavage at the
modiﬁed secondary processing site. Introduction of this
sequence into the endogenous 3D7 parasite msp1 gene
was achieved by targeted homologous recombination, as
convincingly demonstrated by both PCR and IFA, and
eventually resulted in the establishment of viable trans-
genic parasites harbouring the mutation. However, they
grew poorly and, despite our best efforts, could not be
cloned or grown to a sufficiently high parasitaemia to
enable biochemical analysis. This precluded a detailed
characterization of the phenotype. However, we believe
that the most likely explanation for the deleterious effects
of the introduced mutation was that it resulted in prema-
ture shedding of MSP1 as a result of PfSUB1 cleavage at
the modiﬁed secondary processing site following dis-
charge of the protease into the PV just before egress.
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However, there is evidence that it may impact on its capac-
ity to interact with key partner proteins, as well as on its
putative role as an adhesin during invasion. In an investi-
gation of the MSP1/6/7 complex, Kauth et al. (2006) found
thatarecombinantformofMSP6couldinteractwithrecom-
binant MSP138, but not with full-length MSP1, suggesting
thatprimaryprocessingisrequiredforMSP6binding.More
recently, Boyle et al. (2010) demonstrated that the MSP142
processing product – but not full-length MSP1 – binds to
heparin and similar sulphated polysaccharides, suggest-
ingarolefortheprocessedproteininadhesiveinteractions
with erythrocyte surface proteoglycans. Both these ﬁnd-
ings are consistent with the notion that primary processing
functionally activates MSP1, and they will provide valuable
surrogate markers for future work investigating the func-
tional consequences of blocking MSP1 cleavage at spe-
ciﬁc primary processing sites.
In conclusion, our ﬁndings implicate proteolytic pro-
cessing of MSP1 as a highly regulated process that is
important for viability of the asexual blood-stage malaria
parasite. Furthermore, we have established a link
between the ordered proteolytic maturation of this key
merozoite surface component and its function. This
emphasizes the potential of the two enzymes involved –
PfSUB1 and PfSUB2 – as targets for antimalarial drug
development. Finally, our observations add further
support to the notion that the PV has a dual role: it serves
not only as a protective intracellular environment within
which the parasite replicates sequestered from the host
immune system, but also functions as a regulated pro-
cessing compartment in which daughter merozoites
undergo maturation to their full invasive capacity before




precisely mapped [see Koussis et al. (2009) and references
contained therein]. For multiple alignment of regions around
these sites, sequences were taken from P. falciparum MSP1
sequences deposited in PlasmoDB (http://plasmodb.org/
plasmo/) and GenBank (http://www.ncbi.nlm.nih.gov/). The
sequences were also examined in comparison with all depos-
ited MSP1 sequences using WuBlast (http://www.ebi.ac.uk/
Tools/blast2/index.html) and aligned using Clustalw. In each
case, in addition to the 10 residues (P5–P5′) ﬂanking the
cleavage sites, a further 20 amino acids extending beyond the
P5 and P5′ positions were included in the analysis.
Parasite maintenance, transfection and growth assays
Maintenance and synchronization in vitro of asexual blood
stages of P. falciparum clones 3D7 and T9/94, and puriﬁca-
tion of schizonts was as previously described (Blackman
et al., 1994; Yeoh et al., 2007). For determination of parasi-
taemia by ﬂow cytometry, parasite DNA was stained with
hydroethidine (Bergmann-Leitner et al., 2006). Fifty microli-
tres of culture was diluted into 500 ml of PBS in FACS tubes.
Hydroethidine was added directly to the dilute culture to a
ﬁnal concentration of 50 mgm l
-1. The samples were then
incubated in the dark at 37°C for 20 min, then 1 ml of PBS
was then added to each sample to reduce further staining
and the samples kept on ice in the dark for up to 2 h. Samples
were then analysed on a BD FACSCalibur machine, using BD
CellQuest™ Pro V5.2 software. Forward scatter/side scatter
(FS/SS) was adjusted to gate for all cells (G1). Approximate
values FS = E – 1 log, SS = 258 log. Fluorescence detector 2
was set to 309–330 mV, log scale. The red ﬂuorescent popu-
lation was gated as G2. One hundred thousand events were
counted for the entire sample within G1, with G2 counting the
proportion of the 100 000 cells that were ﬂuorescent.
For transfection, ring-stage parasites were electroporated
with plasmid DNA as described previously (Harris et al.,
2005).After initial selection using 2.5 nM WR99210 (Jacobus
Pharmaceuticals, NJ, USA) for approximately 4 weeks, para-
sites were subjected to repeated cycles of drug selection for
3 weeks followed by removal of the drug for 3 weeks (‘drug
cycling’). Clonal populations were obtained by limiting
dilution.
For growth assays, parental and transgenic parasite clones
were tightly synchronized to a 2 h window. Twenty-four hours
later (at mid trophozoite stage), all cultures were adjusted to
0.5% parasitaemia and 2% haematocrit, then triplicate cul-
tures of each clone were set up in 25 cm ﬂasks and parasi-
taemia assessed by FACS at 48 h intervals for the ensuing 10
days (ﬁve cycles). Following each count, the dilution factor
required to adjust the 3D7 control culture back down to a
parasitaemia of approximately 4% was calculated. All the
lines were then all diluted by this same factor, using fresh
erythrocytes in medium at a 2% haematocrit.
MSP1 processing assays
For examination of MSP1 proteolytic processing by PfSUB1,
samples of recombinant MSP1 or parasite-derived native
MSP1 were digested for periods of up to 24 h in an adapta-
tion of a previously described method (Koussis et al., 2009).
Brieﬂy, either 200 mg of full-length recombinant 3D7 MSP1, or
protease inhibitor-treated and saponin-permeabilized 36- to
42-h-old 3D7 or T9/94 schizonts in PfSUB1 digestion buffer
(25 mM HEPES pH 7.4, 12 mM CaCl2) were supplemented
with puriﬁed recombinant PfSUB1 (rPfSUB1) and incubated
at 37°C. Samples taken at intervals were immediately solu-
bilized with SDS-PAGE sample buffer containing 50 mM DTT.
Upon completion of the assay, all samples were subjected to
SDS-PAGE and analysed by Western blot.
Peptides and RP-HPLC
All synthetic peptides used were synthesized by standard
solid-phase Fmoc chemistry either in-house at NIMR or by
BIOMATIK Corporation (http://www.biomatik.com/). Peptide
Ac-CQDMLNISQHC based on the PfSUB2 secondary pro-
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(P.K. Harris, PhD thesis). Preparation of stock and working
solutions of peptides, analysis of peptide cleavage by
RP-HPLC and mass spectrometric identiﬁcation of digestion
products, was as previously described (Koussis et al., 2009).
For quantitative determination of relative initial rates of cleav-
age of equimolar mixtures of peptides, cleavage rates were
compared after no more than 10% of the fastest cleaved
peptide had been hydrolysed, as described previously
(Withers-Martinez et al., 2002).
Expression, puriﬁcation and PfSUB1 digestion of
recombinant Wellcome MSP138/42
The Escherichia coli expression vector pZE23-f38/42, encod-
ing a recombinant form of the C-terminal ‘half’ of the
Wellcome-type MSP1 (termed rMSP138/42) was modiﬁed by
site-directed mutagenesis to replace sequence encoding the
PfSUB2 cleavage site QGML↓NISQ with an artiﬁcial pre-
dicted PfSUB1 cleavage motif, ISGQ↓SETD, creating
plasmid pZE23-f38/42-SUB2to1. Both wild-type and
SUB2to1 mutant vectors were introduced into E. coli strain
BL21 Gold. Induction of expression, puriﬁcation of recombi-
nant protein from inclusion bodies and refolding of the protein
was as described previously (Epp et al., 2003). Refolded
protein was rapidly diluted into PfSUB1 digestion buffer and
used immediately.
Construction of integration constructs pMSP1chimWT
and pMSP1chimSUB2to1
A synthetic gene fragment codon-optimized for expression in
E. coli and encoding the C-terminal region of the Wellcome-
type MSP1 (amino acid residues 1521–1639) was synthe-
sized by Geneart AG and provided as an insert with terminal
BglII and XhoI sites in pGA4 (ampR). The synthetic gene
fragment was excised with BglII and XhoI, and subcloned into
identical sites in the construct pHH1–DSERA4 (a kind gift of
Dr Brendan Crabb, Burnet Institute, Melbourne, Australia) to
create pHH1–ga–MSP1. A 1036 bp upstream region of the
3D7 msp1 coding sequence was ampliﬁed by PCR from 3D7
genomic DNA using forward and reverse primers designed to
incorporate 5′ BclI, and 3′ PstI restriction enzyme sites. The
PCR product was digested with BclI and PstI, and subcloned
into pHH1–ga–MSP1 between the BglII and PstI sites to
create pMSP1chimWT. Sequence encoding the PfSUB2 pro-
cessing site (QGML↓NISQ) in the construct was mutated to
the predicted PfSUB1 cleavage site ISGQ↓SETD by site-
directed mutagenesis using a QuikChange II XL kit (Qiagen).
Sequence ﬂanking this modiﬁed fragment was then excised
with BglII and ClaI and subcloned between identical sites in
pMSP1chimWT to create pMSP1chimSUB2to1. Nucleotide
sequences of all cloned products were conﬁrmed by
sequencing on both strands.
Southern blot and PCR analysis of transgenic
parasite lines
Parasite genomic DNAwas prepared as previously described
(Harris et al., 2005). For Southern blot analysis, DNA was
digested with ClaI and EcoNI (Roche), electrophoresed on a
0.7% agarose gel and transferred to Hybond N Nylon mem-
brane (Amersham Biosciences, Buckinghamshire, UK). Blots
were probed with a [
32P]-labelled, gel-puriﬁed, 480 bp PCR
product ampliﬁed from the 3′ region of the 3D7 msp1 gene.All
oligonucleotide primers were obtained from Eurogentec.
Stock solutions (100 mM in water) were stored at -80°C, and
were used for PCR at a ﬁnal concentration of either 5 or
10 mM. Primers designed to detect integration of transfected
plasmids by PCR were kiMSP1pcrSC-FOR (5′-CCA AGT
GAA AAT AAT AAG AAA GTT AAC G-3′; designed to hybrid-
ize to 3D7 msp1 sequence upstream of the target sequence)
and MSP1intmut-REV (5′-CCA GAT GAC GAA AGC AGC
CGC TGT TCT GC-3′; designed to hybridize speciﬁcally with
recodonized sequence encoding the C-terminal portion of the
Wellcome-type msp1 gene locus). The size of the expected
PCR product, which can only be produced if integration has
correctly taken place, is 1220 bp.
Western blots and antibodies
Western blots were carried out as previously described (Jean
et al., 2003), probing with mAb 89.1 to detect MSP183 (Holder
et al., 1985), mAb X509 or mAb 111.4 to detect 3D7- or
Wellcome-type MSP142 respectively (Holder et al., 1985;
Blackman et al., 1991; Chappel and Holder, 1993; Tolle et al.,
1995), or rabbit antibodies speciﬁc for the Wellcome-type
MSP142 (Blackman et al., 1993).
IFA
Thin blood ﬁlms containing P. falciparum schizonts were air-
dried, ﬁxed in 4% (w/v) paraformaldehyde for 30 min, perme-
abilized in 0.1% (w/v) Triton X-100 for 10 min, washed twice
with PBS for 5 min and then blocked overnight at 4°C in 3%
(w/v) BSA in PBS. Samples were probed with mAb 111.4 for
30 min at 37°C, then washed twice for 5 min in PBS. Sec-
ondary antibody (Alexa Fluor 594-conjugated anti-mouse
IgG) was then applied for 30 min at 37°C. For double-staining
this process was then repeated with the second antibody
(mAb X509) followed by Alex Fluor 488-conjugated anti-
human IgG. Samples were washed, stained with 4,6-
diamidino-2-phenylindole (DAPI) for nuclear staining, then
mounted in Citiﬂuor (Citiﬂuor, UK). Images were acquired
using a Zeiss Axioplan 2 Imaging system (Carl Zeiss,
Germany) and AxioVision 3.1 software. To estimate the pro-
portion of schizonts in transgenic lines expressing chimeric
forms of MSP1, schizonts were doubly probed probed with
the 3D7 type-speciﬁc mAb X509 and the Wellcome type-
speciﬁc mAb 111.4, then the proportion of 111.4-positive sch-
izonts in a total of 2500 X509-positive schizonts estimated
microscopically.
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